{"id":35789,"date":"2026-07-23T17:55:58","date_gmt":"2026-07-23T12:25:58","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35789"},"modified":"2026-07-23T17:56:03","modified_gmt":"2026-07-23T12:26:03","slug":"medtech-news-for-seegene-moon-surgical-cepheid","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid","title":{"rendered":"Seegene USA Advances Infectious Disease Diagnostics with FDA EUA for Multiplex PCR Assay; Synergy Disc\u00ae Achieves 100 U.S. Cases Within 100 Days of FDA Approval; Moon Surgical and KARL STORZ Forge Strategic Commercial Alliance to Expand Scalable Surgery; Cepheid to Showcase Third-Generation GeneXpert\u00ae System at ADLM 2026; Co-Diagnostics and CoSara Launch Clinical Studies in India for PCR-Based Tuberculosis Test; NeoCast Delivers Strong Clinical Outcomes in Chronic Subdural Hematoma in Final First-in-Human EMBO-02 Study"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a63f21776ada\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a63f21776ada\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid\/#Seegene_USA_Received_FDA_Emergency_Use_Authorization_for_Multiplex_PCR_Assay_Advancing_Differential_Diagnosis_of_HSV-1_2_VZV_and_Monkeypox_Virus_for_Ulcerative_Skin_Lesions\" >Seegene USA Received FDA Emergency Use Authorization for Multiplex PCR Assay, Advancing Differential Diagnosis of HSV-1&amp;2, VZV, and Monkeypox Virus for Ulcerative Skin Lesions<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid\/#Synergy_Disc%C2%AE_Reached_100_US_Cases_in_100_Days_Following_FDA_Approval_Advancing_Motion-Preserving_Cervical_Disc_Replacement_in_the_US\" >Synergy Disc\u00ae Reached 100 U.S. Cases in 100 Days Following FDA Approval, Advancing Motion-Preserving Cervical Disc Replacement in the U.S.&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid\/#Moon_Surgical_and_KARL_STORZ_Announced_Strategic_Commercial_Collaboration_to_Advance_Scalable_Surgery\" >Moon Surgical and KARL STORZ Announced Strategic Commercial Collaboration to Advance Scalable Surgery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid\/#Cepheid_to_Unveil_Third-Generation_GeneXpert%C2%AE_System_at_ADLM_2026_Advancing_Molecular_Diagnostic_Capabilities\" >Cepheid to Unveil Third-Generation GeneXpert\u00ae System at ADLM 2026, Advancing Molecular Diagnostic Capabilities&nbsp;&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid\/#Co-Diagnostics_Joint_Venture_CoSara_Initiates_Clinical_Studies_in_India_for_Tuberculosis_Test_on_PCR_Platform\" >Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid\/#Treatment_with_NeoCast_a_Next-Generation_Liquid_Embolic_Results_in_Substantial_Chronic_Subdural_Hematoma_Resolution_and_Functional_Outcome_Gains_in_Final_EMBO-02_First-in-Human_Results\" >Treatment with NeoCast, a Next-Generation Liquid Embolic, Results in Substantial Chronic Subdural Hematoma Resolution and Functional Outcome Gains in Final EMBO-02 First-in-Human Results<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-seegene-usa-received-fda-emergency-use-authorization-for-multiplex-pcr-assay-advancing-differential-diagnosis-of-hsv-1-amp-2-vzv-and-monkeypox-virus-for-ulcerative-skin-lesions\"><span class=\"ez-toc-section\" id=\"Seegene_USA_Received_FDA_Emergency_Use_Authorization_for_Multiplex_PCR_Assay_Advancing_Differential_Diagnosis_of_HSV-1_2_VZV_and_Monkeypox_Virus_for_Ulcerative_Skin_Lesions\"><\/span><strong>Seegene USA Received FDA Emergency Use Authorization for Multiplex PCR Assay, Advancing Differential Diagnosis of HSV-1&amp;2, VZV, and Monkeypox Virus for Ulcerative Skin Lesions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 21 July 2026, Seegene USA received U.S. FDA Emergency Use Authorization (EUA) for its Allplex\u2122 HSV-1&amp;2\/VZV\/MPXV Assay, the first multiplex real-time PCR test in the United States designed to simultaneously detect and differentiate herpes simplex virus types 1 and 2 (HSV-1\/2), varicella-zoster virus (VZV), and monkeypox virus (MPXV) from a single clinical specimen. The authorization strengthened the company&#8217;s molecular diagnostics portfolio, enhanced differential diagnosis of ulcerative skin lesions with overlapping symptoms, and supported broader adoption of multiplex PCR testing in clinical laboratories and infectious disease management.<\/p>\n\n\n\n<p><em>&#8220;Seegene&#8217;s high-multiplex PCR technologies have been widely utilized across global markets,&#8221; said Jun Kim, CEO of Seegene USA. &#8220;This authorization marks an important step in bringing those capabilities more fully into the U.S. market through Seegene USA, enabling the development of locally relevant multiplex diagnostic products that support U.S. clinical laboratories and public-health needs.&#8221;<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/in-vitro-diagnostics-market\"><strong>In Vitro Diagnostics Market Report<\/strong><\/a>,\u201d the global in vitro diagnostics market was valued at <strong>USD 112.80 billion<\/strong> in 2025, growing at a <strong>CAGR of 6%<\/strong> during the forecast period from 2026 to 2034, to reach <strong>USD 189.40 billion<\/strong> by 2034. The in vitro diagnostics market is estimated to register positive revenue growth owing to factors such as the rising global burden of chronic and infectious diseases, which is expanding diagnostic testing volumes, with cardiovascular disease, diabetes, cancer, and respiratory infections driving sustained demand for laboratory and point-of-care testing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-synergy-disc-reached-100-u-s-cases-in-100-days-following-fda-approval-advancing-motion-preserving-cervical-disc-replacement-in-the-u-s-nbsp\"><span class=\"ez-toc-section\" id=\"Synergy_Disc%C2%AE_Reached_100_US_Cases_in_100_Days_Following_FDA_Approval_Advancing_Motion-Preserving_Cervical_Disc_Replacement_in_the_US\"><\/span><strong>Synergy Disc\u00ae Reached 100 U.S. Cases in 100 Days Following FDA Approval, Advancing Motion-Preserving Cervical Disc Replacement in the U.S.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 21 July 2026, Synergy Spine Solutions announced that its Synergy Disc\u00ae reached 100 cervical disc replacement procedures in the United States within 100 days of its first commercial implantation following FDA Premarket Approval. The milestone reflected strong early clinical adoption of the motion-preserving artificial cervical disc, which was designed to maintain cervical spine mobility while improving spinal alignment. The company attributed the rapid uptake to growing surgeon preference for advanced cervical disc replacement technologies supported by favorable clinical outcomes and long-term international experience.<\/p>\n\n\n\n<p><em>&#8220;For years, our focus has been on preserving motion because that is fundamental to healthy cervical spine function,&#8221; said Dr. Todd Lanman, a spinal neurosurgeon who participated in the Synergy Disc (1-Level) IDE trial and performed the first commercial Synergy Disc procedure in the United States. &#8220;As cervical disc replacement continues to evolve, we&#8217;re also recognizing the importance of restoring cervical alignment. Synergy combines motion preservation with alignment restoration to better replicate the spine&#8217;s natural biomechanics.&#8221;<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/spinal-implants-market\"><strong>Spinal Implants Market Report<\/strong><\/a>,\u201d the global Spinal Implants Market was valued at <strong>USD 14,324.12 million<\/strong> in 2024, growing at a <strong>CAGR of 5.50%<\/strong> during the forecast period from 2025 to 2032 to reach <strong>USD 21,899.24 million<\/strong> by 2032. The rising cases of spinal disorders, particularly among aging populations, have significantly increased the demand for corrective surgical interventions. Simultaneously, the surge in sports-related and accident-induced spinal injuries is fueling the need for advanced implantable solutions. Moreover, there is a growing preference for non-fusion and motion preservation devices that maintain spinal mobility and enhance patient outcomes, especially among younger and more active individuals. Coupled with this is the uptick in product development activities and technological innovations by key market players globally, which is expanding the range of available solutions and improving surgical success rates. Together, these trends are accelerating the adoption of Spinal Implants and driving the overall market during the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-moon-surgical-and-karl-storz-announced-strategic-commercial-collaboration-to-advance-scalable-surgery\"><span class=\"ez-toc-section\" id=\"Moon_Surgical_and_KARL_STORZ_Announced_Strategic_Commercial_Collaboration_to_Advance_Scalable_Surgery\"><\/span><strong>Moon Surgical and KARL STORZ Announced Strategic Commercial Collaboration to Advance Scalable Surgery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 22 July 2026, Moon Surgical and KARL STORZ entered into a strategic commercial collaboration to accelerate the adoption of scalable minimally invasive surgery. Through the partnership, KARL STORZ supported the commercialization of Moon Surgical&#8217;s Maestro\u00ae System by leveraging its extensive sales network and expertise in surgical visualization. The collaboration aimed to enhance operating room efficiency, improve surgical team workflows, and expand access to robotic-assisted procedures across hospitals and ambulatory surgery centers, thereby advancing the adoption of scalable surgical technologies.<\/p>\n\n\n\n<p><em>&#8220;Scalable Surgery depends on the operating room ecosystem working together, not on any one single device. By bringing Maestro&#8217;s capabilities together with KARL STORZ, we can give surgical teams a more capable operating room and make advanced laparoscopic surgery easier to access and adopt. This collaboration helps us reach more surgeons and more sites of care, which is exactly where Scalable Surgery can do the most good for patients and hospitals,&#8221; said Anne Osdoit, CEO of Moon Surgical.<\/em><\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/surgical-robotic-system-market\"><strong>Surgical Robotic Systems Market Report<\/strong><\/a>,\u201d the global surgical robotic system market size is expected to increase from <strong>USD 11,082.32 million<\/strong> in 2025 to <strong>USD 29,785.13 million<\/strong> by 2034, growing at a <strong>CAGR of 13.21% <\/strong>during the forecast period from 2026 to 2034. The rising incidence of chronic disorders such as cancer, cardiovascular diseases, and orthopedic conditions is significantly boosting the demand for advanced surgical interventions, thereby propelling the growth of the Surgical Robotic Systems Market. As chronic conditions often require complex, high-precision surgeries, robotic-assisted procedures offer enhanced accuracy, minimal invasiveness, and quicker recovery times, making them highly suitable for treating such ailments. Simultaneously, the increasing number of surgical procedures globally, driven by a growing aging population and a higher prevalence of lifestyle-related health issues, is further escalating the need for efficient and precise surgical tools. In response, key Surgical Robotic System Companies are heavily investing in product development activities, focusing on innovations such as compact robotic platforms, AI integration, and enhanced visualization systems. These advancements not only expand the scope of robotic surgery across specialties but also improve surgical outcomes, thereby contributing to the growth of the Surgical Robotic Systems Market Forecast Period from 2026 to 2034.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cepheid-to-unveil-third-generation-genexpert-system-at-adlm-2026-advancing-molecular-diagnostic-capabilities-nbsp-nbsp\"><span class=\"ez-toc-section\" id=\"Cepheid_to_Unveil_Third-Generation_GeneXpert%C2%AE_System_at_ADLM_2026_Advancing_Molecular_Diagnostic_Capabilities\"><\/span><strong>Cepheid to Unveil Third-Generation GeneXpert\u00ae System at ADLM 2026, Advancing Molecular Diagnostic Capabilities&nbsp;&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 22 July 2026, Cepheid announced the introduction of its third-generation GeneXpert\u00ae System at ADLM 2026, marking a significant advancement in molecular diagnostic technology. The newly unveiled platform was developed to enhance laboratory productivity by offering expanded testing capabilities, improved workflow efficiency, and greater scalability while maintaining compatibility with existing GeneXpert assays. The next-generation system was intended to help clinical laboratories meet growing diagnostic demands, strengthen operational performance, and improve access to rapid, accurate molecular testing across a wide range of healthcare settings.<\/p>\n\n\n\n<p><em>&#8220;Healthcare providers increasingly need access to different types of molecular testing, yet those capabilities are often spread across multiple instruments and workflows,&#8221; said Connie Savor, Chief Medical Officer at Cepheid. &#8220;The third-generation GeneXpert system is designed to bring a broader spectrum of molecular diagnostic capabilities onto a single system, helping clinicians access the insights they need to make informed decisions across the continuum of care. This launch serves as an example of how Cepheid and Danaher are helping solve some of the hardest problems in healthcare with global partners, including clinicians.&#8221;<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/molecular-diagnostics-market\"><strong>Molecular Diagnostic Market Report<\/strong><\/a>\u201d, the global molecular diagnostics market was valued at<strong> USD 10.44 billion<\/strong> in 2025 and is projected to reach <strong>USD 23.05 billion<\/strong> by 2034. The market is expected to expand at a <strong>CAGR of 9.21%<\/strong> during the forecast period 2026-2034. Molecular diagnostics comprises highly sensitive and specific laboratory methods that detect and identify biomarkers at the nucleic acid level, analyzing DNA and RNA to support medical diagnosis, prognosis, disease monitoring, and the selection of optimal treatment. The category is built on a set of core technologies, foremost among them the polymerase chain reaction, which amplifies specific DNA or RNA sequences and enables the detection of minute quantities of genetic material, together with sequencing, in situ hybridization, and microarray analysis. The commercial market comprises the instruments that automate nucleic acid extraction, amplification, and detection; the reagents, assays, and consumable cartridges consumed with every test performed; and the software and services that support result interpretation. Clinically, molecular diagnostics is applied across three principal domains: infectious disease diagnosis, where it identifies pathogens such as human immunodeficiency virus, hepatitis B and C, influenza, human papillomavirus, tuberculosis, and respiratory and gastrointestinal organisms, and quantifies viral load and drug resistance; oncology testing, where it detects gene mutations and translocations, supports companion diagnostics, and enables liquid biopsy; and genetic testing for inherited disorders, prenatal assessment, and hereditary risk. The contemporary market is defined by the migration of testing from centralized reference laboratories toward near-patient and point-of-care settings, the rapid expansion of multiplex syndromic panels that identify multiple pathogens from a single sample within an hour, and the growing integration of automation and data interpretation tools that reduce manual handling and shorten turnaround time.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-co-diagnostics-joint-venture-cosara-initiates-clinical-studies-in-india-for-tuberculosis-test-on-pcr-platform-nbsp\"><span class=\"ez-toc-section\" id=\"Co-Diagnostics_Joint_Venture_CoSara_Initiates_Clinical_Studies_in_India_for_Tuberculosis_Test_on_PCR_Platform\"><\/span><strong>Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 22 July 2026, Co-Diagnostics announced that its Indian joint venture, CoSara Diagnostics, initiated clinical studies to evaluate its PCR-based tuberculosis (TB) test on the CoSara PCR Pro\u00ae platform in select laboratories across India. The milestone followed the deployment of PCR Pro instruments, TB test kits, and proprietary sample preparation systems to support the studies. The company planned to manufacture and distribute the PCR platform and associated assays under the CoSara brand in India, to expand access to rapid, decentralized molecular TB diagnostics and strengthen the availability of high-quality PCR testing in regions with a significant tuberculosis burden.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201d<a href=\"https:\/\/www.delveinsight.com\/report-store\/polymerase-chain-reaction-market\"><strong>Polymerase Chain Reaction Market Report<\/strong><\/a>,\u201d the global polymerase chain reaction market was valued at <strong>USD 4.90 billion<\/strong> in 2023, growing at a<strong> CAGR of 8.66% <\/strong>during the forecast period from 2024 to 2030 to reach <strong>USD 8.04 billion<\/strong> by 2030. The PCR market is slated to witness increasing revenue owing to factors such as a rise in the prevalence of diseases caused by pathogens, increasing applications in the field of clinical diagnostics, along with the latest technological advancements to further enhance its accuracy, which is expected to result in the Polymerase Chain Reaction market growth during the forecast period (2024-2030).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treatment-with-neocast-a-next-generation-liquid-embolic-results-in-substantial-chronic-subdural-hematoma-resolution-and-functional-outcome-gains-in-final-embo-02-first-in-human-results\"><span class=\"ez-toc-section\" id=\"Treatment_with_NeoCast_a_Next-Generation_Liquid_Embolic_Results_in_Substantial_Chronic_Subdural_Hematoma_Resolution_and_Functional_Outcome_Gains_in_Final_EMBO-02_First-in-Human_Results\"><\/span><strong>Treatment with NeoCast, a Next-Generation Liquid Embolic, Results in Substantial Chronic Subdural Hematoma Resolution and Functional Outcome Gains in Final EMBO-02 First-in-Human Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On 22 July 2026, Arsenal Medical announced the final first-in-human results from its EMBO-02 clinical trial, demonstrating that treatment with its next-generation liquid embolic agent, NeoCast\u2122, achieved substantial resolution of chronic subdural hematomas (cSDH) while significantly improving patients&#8217; functional outcomes. The study also reported favorable safety and feasibility outcomes, supporting NeoCast&#8217;s potential as an advanced embolic material for middle meningeal artery embolization in the treatment of cSDH. These findings reinforced the promise of NeoCast as a differentiated liquid embolic technology for neurovascular interventions and supported its continued clinical development.<\/p>\n\n\n\n<p><em>&#8220;These NeoCast results are encouraging in ways that could have meaningful implications for both physicians and patients,&#8221; said Tim Phillips, MBBS, GDSA, FRANZCR, interventional neuroradiologist at the Neuro-Intervention and Imaging Service of Western Australia (NIISwa), Sir Charles Gairdner Hospital in Perth, Western Australia, and an investigator in the EMBO-02 study. &#8220;In my experience, NeoCast demonstrated highly predictable distal penetration, allowing effective embolization without the need to advance the microcatheter deep into the target vasculature, which simplified and streamlined the procedure. Equally important, because NeoCast is free of toxic solvents, patients experienced a virtually pain-free injection. The ability to perform middle meningeal artery embolization without sedation represents a meaningful advancement in patient care.&#8221;<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/neurovascular-embolization-devices-market\"><strong>Neurovascular Embolization Devices Market Report<\/strong><\/a>,\u201d the neurovascular embolization devices market was valued at <strong>USD 1,347.66 million<\/strong> in 2024, growing at a <strong>CAGR of 4.40% <\/strong>during the forecast period from 2025 to 2032, to reach <strong>USD 1,890.84 million<\/strong> by 2032. The rising prevalence of neurovascular disorders such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes is significantly driving the global market for neurovascular embolization devices. These conditions often require precise, minimally invasive treatments, for which embolization devices are critical. Additionally, the global increase in hypertension, a major risk factor for neurovascular diseases, has led to a higher incidence of brain hemorrhages and aneurysms, further fueling demand for effective embolization solutions.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Seegene USA Received FDA Emergency Use Authorization for Multiplex PCR Assay, Advancing Differential Diagnosis of HSV-1&amp;2, VZV, and Monkeypox Virus for Ulcerative Skin Lesions On 21 July 2026, Seegene USA received U.S. FDA Emergency Use Authorization (EUA) for its Allplex\u2122 HSV-1&amp;2\/VZV\/MPXV Assay, the first multiplex real-time PCR test in the United States designed to simultaneously [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35793,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18956,17021,16975,18937,22419,2242,19106,19028],"industry":[17226],"therapeutic_areas":[17278],"class_list":["post-35789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-in-vitro-diagnostics","tag-medical-devices-market","tag-medtech-market","tag-molecular-diagnostic","tag-neurovascular-embolization-devices","tag-polymerase-chain-reaction","tag-spinal-implants","tag-surgical-robotic-systems","industry-medical-devices","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MedTech News | Seegene USA, Moon Surgical, Cepheid<\/title>\n<meta name=\"description\" content=\"Seegene USA\u2019s Multiplex PCR Assay; Synergy Spine Solutions\u2019 Synergy Disc; Moon Surgical and KARL STORZ\u2019s Collaboration\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Seegene USA, Moon Surgical, Cepheid\" \/>\n<meta property=\"og:description\" content=\"Seegene USA\u2019s Multiplex PCR Assay; Synergy Spine Solutions\u2019 Synergy Disc; Moon Surgical and KARL STORZ\u2019s Collaboration\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-23T12:25:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-23T12:26:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-seegene-moon-surgical-cepheid.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Seegene USA, Moon Surgical, Cepheid","description":"Seegene USA\u2019s Multiplex PCR Assay; Synergy Spine Solutions\u2019 Synergy Disc; Moon Surgical and KARL STORZ\u2019s Collaboration","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Seegene USA, Moon Surgical, Cepheid","og_description":"Seegene USA\u2019s Multiplex PCR Assay; Synergy Spine Solutions\u2019 Synergy Disc; Moon Surgical and KARL STORZ\u2019s Collaboration","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-07-23T12:25:58+00:00","article_modified_time":"2026-07-23T12:26:03+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-seegene-moon-surgical-cepheid.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"Seegene USA Advances Infectious Disease Diagnostics with FDA EUA for Multiplex PCR Assay; Synergy Disc\u00ae Achieves 100 U.S. Cases Within 100 Days of FDA Approval; Moon Surgical and KARL STORZ Forge Strategic Commercial Alliance to Expand Scalable Surgery; Cepheid to Showcase Third-Generation GeneXpert\u00ae System at ADLM 2026; Co-Diagnostics and CoSara Launch Clinical Studies in India for PCR-Based Tuberculosis Test; NeoCast Delivers Strong Clinical Outcomes in Chronic Subdural Hematoma in Final First-in-Human EMBO-02 Study","datePublished":"2026-07-23T12:25:58+00:00","dateModified":"2026-07-23T12:26:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid"},"wordCount":2021,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-seegene-moon-surgical-cepheid.webp","keywords":["In Vitro Diagnostics","Medical Devices Market","MedTech Market","Molecular Diagnostic","Neurovascular Embolization Devices","polymerase chain reaction","Spinal Implants","Surgical Robotic Systems"],"articleSection":["Notizia - Recent Pharma, Healthcare and Biotech Happenings"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid","name":"MedTech News | Seegene USA, Moon Surgical, Cepheid","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-seegene-moon-surgical-cepheid.webp","datePublished":"2026-07-23T12:25:58+00:00","dateModified":"2026-07-23T12:26:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Seegene USA\u2019s Multiplex PCR Assay; Synergy Spine Solutions\u2019 Synergy Disc; Moon Surgical and KARL STORZ\u2019s Collaboration","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-seegene-moon-surgical-cepheid#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-seegene-moon-surgical-cepheid.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-seegene-moon-surgical-cepheid.webp","width":772,"height":482,"caption":"medtech-news-for-seegene-moon-surgical-cepheid"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/medtech-news-for-seegene-moon-surgical-cepheid-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">In Vitro Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Molecular Diagnostic<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurovascular Embolization Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">polymerase chain reaction<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spinal Implants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Surgical Robotic Systems<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">In Vitro Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Molecular Diagnostic<\/span>","<span class=\"advgb-post-tax-term\">Neurovascular Embolization Devices<\/span>","<span class=\"advgb-post-tax-term\">polymerase chain reaction<\/span>","<span class=\"advgb-post-tax-term\">Spinal Implants<\/span>","<span class=\"advgb-post-tax-term\">Surgical Robotic Systems<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 day ago","modified":"Updated 1 day ago"},"absolute_dates":{"created":"Posted on Jul 23, 2026","modified":"Updated on Jul 23, 2026"},"absolute_dates_time":{"created":"Posted on Jul 23, 2026 5:55 pm","modified":"Updated on Jul 23, 2026 5:56 pm"},"featured_img_caption":"medtech-news-for-seegene-moon-surgical-cepheid","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35789"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35789\/revisions"}],"predecessor-version":[{"id":35790,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35789\/revisions\/35790"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35793"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35789"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35789"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}